1 active not recruiting, 1 recruiting. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Smoldering Systemic Mastocytosis: new trials by email Literature Review of Smoldering Systemic Mastocytosis trials Research Report on Smoldering Systemic Mastocytosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B), Placebo Tablets - SSM, Mastocytosis, Indolent | Phase 2 | Active not recruiting | Cogent Biosciences, Inc. | 237 | 2022-06-27 | 2026-10-22 |
| (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis Elenestinib, Placebo - Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis | Phase 2 / Phase 3 | Recruiting | Blueprint Medicines Corporation | 534 | 2021-11-30 | 2026-10-07 |
Mastocytosis, Systemic (2) · Hematologic Diseases (1) · Hypersensitivity (1) · Immune Complex Diseases (1) · Immune System Diseases (1) · Mastocytosis (1)
Mast Cell Activation Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Connective Tissue (2) · Neoplasms, Connective and Soft Tissue (2) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Mastocytosis (1)
Blueprint Medicines Corporation (1) · Cogent Biosciences, Inc. (1)
Australia (2) · Belgium (2) · Czechia (2) · France (2) · Germany (2) · Ireland (2) · Italy (2) · Netherlands (2) · Norway (2) · Poland (2) · Spain (2) · Switzerland (2) · United Kingdom (2) · United States (2) · Argentina (1)